STMN2. STMN3. and STMN4 belong to the stathmin family of microtubule-destabilizing proteins, which regulate cytoskeletal dynamics by interacting with tubulin and promoting microtubule disassembly. These proteins share a conserved stathmin-like domain but exhibit distinct expression patterns and functional roles. STMN2 (SCG10) is predominantly expressed in neurons, where it supports axonal growth, synaptic plasticity, and nerve regeneration. Its dysregulation is linked to neurodegenerative disorders like Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). STMN3 (SCG6) is enriched in the peripheral nervous system and may influence neurodevelopment or tumorigenesis, though its functions remain less characterized. STMN4 (RB3) shows broader tissue expression and is implicated in cell cycle regulation and cancer progression, particularly in gliomas and breast cancer.
Antibodies targeting STMN2/3/4 are critical tools for studying their localization, expression levels, and interactions in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore roles in neural repair, cancer metastasis, or drug resistance. Specific antibodies help distinguish between these paralogs due to their structural similarities. Commercial antibodies are often validated for cross-reactivity and specificity across human, mouse, or rat models. Research leveraging these antibodies has advanced understanding of their contributions to microtubule dynamics, intracellular trafficking, and disease mechanisms, highlighting their potential as therapeutic targets or biomarkers.